Industry, FDA begin to hammer out PDUFA VII details

Discussions continue between industry and the FDA regarding the upcoming reauthorization of user fees for prescription drugs, biologics and generic drugs. After public hearing and a first round of meetings that gave a peek into priorities for industry and regulator representatives, this next round began to sort out some detail.